"DU 145人前列腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

正確的細(xì)胞復(fù)蘇需知事項(xiàng)：細(xì)胞凍存HAO了，接下來要注意什么問題呢？沒錯(cuò)，就是記得到時(shí)間了，拿出來復(fù)蘇。那么，細(xì)胞復(fù)蘇的過程中又有哪些該注意的事項(xiàng)呢？細(xì)胞活力和形態(tài)檢查的作用何在？活力檢查——千萬不要使用不健康的細(xì)胞，可能有污染(真菌、支原體等)，如果發(fā)現(xiàn)有污染毫不猶豫的丟棄!形態(tài)檢查——檢查細(xì)胞的固有形態(tài)和生長行為。凍存細(xì)胞：補(bǔ)充新的培養(yǎng)——在您開始凍存細(xì)胞的前一天補(bǔ)充新的培養(yǎng)。在細(xì)胞長至７０%單層時(shí)收獲細(xì)胞，計(jì)數(shù)活細(xì)胞數(shù)，用凍存調(diào)整細(xì)胞密度~５ x１０６  s/ml (根據(jù)不同的細(xì)胞類型調(diào)整)；凍存——用凍存洗細(xì)胞并用凍存重懸細(xì)胞，有不同類型的凍存，根據(jù)細(xì)胞類型選擇Zui合適的凍存(常用的凍存成分有)：５-１０% DMSO——注意確保DMSO不含有其他的毒性物質(zhì)；５-１５%甘油；如果細(xì)胞在無血清培養(yǎng)基內(nèi)生長，應(yīng)在５０%條件培養(yǎng)基內(nèi)(細(xì)胞在無血清培養(yǎng)基內(nèi)生長２４小時(shí))內(nèi)凍存和復(fù)蘇。在凍存管上標(biāo)記HAO細(xì)胞類型，日期，凍存人等信息，并保證每凍存管不超過１.５ml。放入罐之前記錄凍存管的數(shù)量和位置。以Zui快的速度轉(zhuǎn)移凍存管知罐內(nèi)，因此，此步驟ZuiHAO使用干冰，或者把凍存管浸入裝有的小盒內(nèi)。此外還要注意，在凍存管上沒有足夠的空間記錄細(xì)胞的詳細(xì)信息，做HAO記錄是非常非常重要的！還有一個(gè)Zui重要的，一定要在異地的罐內(nèi)保存同樣的一份細(xì)胞，以免其中的一個(gè)罐出現(xiàn)問題！細(xì)胞正確的復(fù)蘇方式和正確的凍存方式同樣重要，熟記以下要點(diǎn)：當(dāng)從罐內(nèi)取出細(xì)胞時(shí)，有可能會(huì)出現(xiàn)凍存管破裂的情況，使用保護(hù)面罩和防護(hù)服十分必要；其實(shí)，細(xì)胞復(fù)蘇只是一個(gè)簡單的實(shí)驗(yàn)，不過這其中卻不可避免有一些需要注意的細(xì)節(jié)，不然，也不一定會(huì)盡如人意。例如說，人身健康方面：一定要記得做HAO防凍工作，戴上護(hù)目鏡；盡量降低DMSO對(duì)細(xì)胞的損傷等等。

換液周期：每周2-3次

8305-C Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６傳代;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CDC/EU.HMEC-1細(xì)胞、TGHAVSMC細(xì)胞、MCF12F細(xì)胞

HCC202 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NKM1細(xì)胞、WEHI 164 TC細(xì)胞、SUDHL16細(xì)胞

NCI-H2087 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：懸浮生長，有少數(shù)細(xì)胞疏松貼壁;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SW962細(xì)胞、2B4細(xì)胞、KYSE30細(xì)胞

DU 145人前列腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

背景信息：DU １４５ 是從一位有３年淋巴細(xì)胞白血病史的前列腺癌患者的腦部轉(zhuǎn)移灶中建立的。該細(xì)胞系未檢測到激素敏感性，性酶陽性，單個(gè)的細(xì)胞可在軟瓊脂中形成集落。對(duì)此細(xì)胞和原始腫瘤的亞顯微結(jié)構(gòu)分析可見微絨毛、微絲、細(xì)胞橋粒、線粒體、發(fā)達(dá)的高爾基體和異質(zhì)溶酶體。該細(xì)胞不表達(dá)前列腺抗原。

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

ST Cells;背景說明：ST細(xì)胞系建系于１９６０年（Mcclurkin,AW,etal）。ST細(xì)胞一般用于病毒增殖和分離，是豬細(xì)小病毒的理想宿主，可用于這類病毒的分離及增殖。;傳代方法：１：３傳代,２-３天傳一代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HGF-1細(xì)胞、THPI細(xì)胞、RGM-1細(xì)胞

CHG5 Cells;背景說明：少突神經(jīng)膠質(zhì)瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BE2-M17細(xì)胞、OCI-Ly1細(xì)胞、UCLA-SO-M20細(xì)胞

WM239A Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC-3M-IE8細(xì)胞、OVCAR420細(xì)胞、TCMK1細(xì)胞

DAN-G Cells;背景說明：胰腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：aNK細(xì)胞、MC 3T3-E1細(xì)胞、Ramos-2G6-4C10細(xì)胞

DU 145人前列腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

物種來源：人源、鼠源等其它物種來源

形態(tài)特性：上皮細(xì)胞樣

實(shí)驗(yàn)室細(xì)胞培養(yǎng)基知識(shí)簡介：干粉培養(yǎng)基：以前大部分實(shí)驗(yàn)室都是用干粉培養(yǎng)基，但配制過程就較為繁瑣，要溶解、調(diào)pH值，過濾，過程中可能會(huì)產(chǎn)生一些濃度誤差，而且有些實(shí)驗(yàn)室的水質(zhì)并不理想，所以培養(yǎng)的效果會(huì)有差異。如果使用體培養(yǎng)基，這種人為的誤差會(huì)減少，因?yàn)楫吘故谴笈抗I(yè)化生產(chǎn)的，批間差會(huì)很小。大家是不是感覺體培養(yǎng)基會(huì)貴很多，以前是這樣，但現(xiàn)在大家都認(rèn)同了；無血清培養(yǎng)基(Serum-Free Media)，通常以SFM表示，顧名思義，就是在細(xì)胞培養(yǎng)中不需要添加血清，但是在某些應(yīng)用中可能要添加生長因子或細(xì)胞因子。無血清培養(yǎng)基中添加了血清的主要成分：粘附因子、生長因子、必需的營養(yǎng)物質(zhì)和激素等，能減少上述血清帶來的不利因素，使細(xì)胞培養(yǎng)的條件更穩(wěn)定。但它也不是完美的，從有血清培養(yǎng)過渡到無血清培養(yǎng)的條件并不像想象中那么直截了當(dāng)。處于發(fā)育的不同分化階段的細(xì)胞(例如干細(xì)胞與定向前體細(xì)胞相比)需要不同的配方，對(duì)生長因子和細(xì)胞因子的選擇尤為重要。而且在去除血清的同時(shí)，也去除了一些血清蛋白具有的保護(hù)、解毒作用，因此對(duì)試劑、水的純度和儀器清潔度的要求更GAO。另外，它的價(jià)格也比普通的培養(yǎng)基貴很多。

Nthy ori 3.1 Cells;背景說明：甲狀腺；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKOV-3細(xì)胞、CAMA1細(xì)胞、RDES細(xì)胞

HCC-1359 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUM-159PT細(xì)胞、NIH:OVCAR-4細(xì)胞、Karpas-299細(xì)胞

MD Anderson-Metastatic Breast-415 Cells;背景說明：這株細(xì)胞表達(dá)WNT７B癌基因。８１６８０８８].帶瘤患者來自巴拉圭，雖然填報(bào)的是白人，但細(xì)胞表型存在G６PDＡ型，顯示其屬于混血。細(xì)胞株形成平展延伸的上皮細(xì)胞樣，在電鏡下呈現(xiàn)結(jié)節(jié)，伴隨著延伸的微管和微板。不容易用胰酶消化。;傳代方法：消化５-１０分鐘。１：２。４-５天長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：GM17219細(xì)胞、UACC-812細(xì)胞、D-324 Med細(xì)胞

LA-795 Cells;背景說明：肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NR 8383細(xì)胞、HTori 3細(xì)胞、DHL6細(xì)胞

Hx-147 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PLB 985細(xì)胞、MES-23.5細(xì)胞、PG-4細(xì)胞

NCIH1355 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HMSC細(xì)胞、D341細(xì)胞、T. T細(xì)胞

SW 527 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UMUC-3細(xì)胞、H1435細(xì)胞、A375-S2細(xì)胞

NMC-G1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：MB157細(xì)胞、HLCL9B10細(xì)胞、PanC1細(xì)胞

Hs729T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NIHOVCAR3細(xì)胞、EJ細(xì)胞、MDA361細(xì)胞

QBI-293A Cells;背景說明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：G401細(xì)胞、C33-A細(xì)胞、Hs729細(xì)胞

SR-786 Cells;背景說明：間變性大細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI/AML-4細(xì)胞、EFM-192B細(xì)胞、SK-RC-52細(xì)胞

H4-II-E Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hmy.2 CIR細(xì)胞、PANC 203細(xì)胞、624細(xì)胞

H-1238 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ARH77細(xì)胞、Anip[973]細(xì)胞、THLE-3細(xì)胞

MD Anderson-Metastatic Breast-361 Cells;背景說明：該細(xì)胞源自４０歲女性乳腺癌的腦轉(zhuǎn)移組織。;傳代方法： １：２—１：６傳代，每周換液２—３次;生長特性：松散貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：OCILY10細(xì)胞、RCC23細(xì)胞、CRFK細(xì)胞

EA hy 926 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：GM00637B細(xì)胞、SUDHL-6細(xì)胞、HS-68細(xì)胞

NCI-HUT-596 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：675T細(xì)胞、A 253細(xì)胞、CWR22Rv1細(xì)胞

P30-OHKUBO Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：BALB/3T3 (clone A31)細(xì)胞、SW13細(xì)胞、Renal Carcinoma細(xì)胞

DU 145人前列腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

Abcam HCT 116 CR2 KO Cells(提供STR鑒定圖譜)

AG05278 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSI398 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RST527 Cells(提供STR鑒定圖譜)

BHK570 Cells(提供STR鑒定圖譜)

CHP-100S Cells(提供STR鑒定圖譜)

DA03125 Cells(提供STR鑒定圖譜)

ESi045-C Cells(提供STR鑒定圖譜)

GM07166VA7-NBS1 Cells(提供STR鑒定圖譜)

Ku812F Cells;背景說明：慢性粒細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：159PT細(xì)胞、GC-2細(xì)胞、CD-18細(xì)胞

HT-3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE353.SK細(xì)胞、SK-N-BE2細(xì)胞、WM-239細(xì)胞

Mel RM Cells;背景說明：黑色素瘤；神經(jīng)節(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MFC細(xì)胞、HEK-293-F細(xì)胞、H2135細(xì)胞

SW-1271 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HeLa/S3細(xì)胞、HEK293T/17細(xì)胞、DLD 1細(xì)胞

T-47-D Cells;背景說明：浸潤性導(dǎo)管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BTI-TN5B1-4細(xì)胞、Panc_08_13細(xì)胞、KMST6細(xì)胞

NCIH2030 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：DoHH-2細(xì)胞、RH-30細(xì)胞、GP2-293細(xì)胞

anti-delta-crystallin Cells(提供STR鑒定圖譜)

Medical Research Council cell strain-9 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH441細(xì)胞、T24(ECV304)細(xì)胞、H4-II-E-C3細(xì)胞

SKHEP1 Cells;背景說明：SK-HEP-１細(xì)胞系已被鑒定為內(nèi)皮來源。該細(xì)胞系為異倍體女性人（XX），染色體在亞三倍體范圍內(nèi)。在裸鼠中，它能形成與肝癌相一致的大細(xì)胞癌;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Rat 1細(xì)胞、Human Liver-7702細(xì)胞、KHYG1細(xì)胞

NCI-H1092 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：隨細(xì)胞的密度而增加;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RPMI 2650細(xì)胞、COR-L105細(xì)胞、KOSC-2細(xì)胞

143BTK- Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：混合型;相關(guān)產(chǎn)品有：H9細(xì)胞、NCIH1770細(xì)胞、HCEC細(xì)胞

HPDE6c7 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：B16F1細(xì)胞、BCPAP細(xì)胞、RCC 786-O細(xì)胞

CFPAC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１０傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：NCIH524細(xì)胞、HEL9217細(xì)胞、DMS-153細(xì)胞

MyLa 2059 Cells;背景說明：皮膚；T淋巴細(xì)胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：B16 melanoma細(xì)胞、KYSE 520細(xì)胞、mRTEC細(xì)胞

HepG2/C3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SUM-102PT細(xì)胞、HUCCT1細(xì)胞、LS411細(xì)胞

HAM006 Cells(提供STR鑒定圖譜)

HAP1 RXRB (-) 1 Cells(提供STR鑒定圖譜)

WM35 Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A-172細(xì)胞、293F細(xì)胞、H-2286細(xì)胞

KU19-19 Cells;背景說明：膀胱癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LTEPa2細(xì)胞、GalK1細(xì)胞、PLB-985細(xì)胞

HEC1B Cells;背景說明：該細(xì)胞是H.Kuramoto１９６８年分離的HEC-１-A細(xì)胞亞株。不同於HEC-A-１的是：該亞株在培養(yǎng)第１３５天到１９０天之間表現(xiàn)出穩(wěn)定的生長周期，且重現(xiàn)扁平，與親本細(xì)胞系相比更具鋪路石式樣。此外主要染色體組是親本細(xì)胞的兩倍。;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：PTK 2細(xì)胞、MIMVEC細(xì)胞、OE-21細(xì)胞

HHFK Cells;背景說明：毛囊；角質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEMCSS細(xì)胞、MDA-MB-134細(xì)胞、Michigan Cancer Foundation-10A細(xì)胞

HCC-202 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：RT4細(xì)胞、NB1-RGB細(xì)胞、ND7/23細(xì)胞

OVCAR3 Cells;背景說明：該細(xì)胞１９８２年由T.C. Hamilton等建系，源自一位６０卵巢腺癌的腹水，是卵巢癌抗藥性研究的模型。;傳代方法：１：２—１：４傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：BLO-11細(xì)胞、SNB.19細(xì)胞、NCI-H711細(xì)胞

COLO394 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：373 MG細(xì)胞、BE2-M17細(xì)胞、RGM1細(xì)胞

H-2227 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：該細(xì)胞既有懸浮生長，又有貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HT1197細(xì)胞、HUT 125細(xì)胞、J.E6-1細(xì)胞

HyCyte bEnd.3 KO-mCdh5 Cells(提供STR鑒定圖譜)

LB2586-MEL Cells(提供STR鑒定圖譜)

MyLa 1850 Cells(提供STR鑒定圖譜)

OUMS-21 [1972] Cells(提供STR鑒定圖譜)

RPMI-7711 Cells(提供STR鑒定圖譜)

UCLA 8 Cells(提供STR鑒定圖譜)

ZP102 Cells(提供STR鑒定圖譜)

HG01499 Cells(提供STR鑒定圖譜)

LICR-HN-6 Cells;背景說明：舌鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MB468細(xì)胞、38C-13細(xì)胞、Roswell Park Memorial Institute 6666細(xì)胞

SK-N-BE2 Cells;背景說明：１９７２年１１月從一們多次化療及放療的擴(kuò)散性神經(jīng)母細(xì)胞瘤患兒骨髓穿刺物中建立了SK-N-BE(２)神經(jīng)母細(xì)胞瘤細(xì)胞株。 該細(xì)胞顯示中等水平的多巴胺-β-羥基酶活性。 有報(bào)道稱SK-N-BE(２)細(xì)胞的飽和濃度超過１x１０６細(xì)胞/平方厘米。細(xì)胞形態(tài)多樣，有的有長突觸，有的呈上皮細(xì)胞樣。 細(xì)胞會(huì)聚集，形成團(tuán)塊并浮起;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SNT8細(xì)胞、NCI-H676B細(xì)胞、SUM159細(xì)胞

NALM 6 Cells;背景說明：急性B淋巴細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-1386細(xì)胞、BT-549細(xì)胞、EC-109細(xì)胞

RPE-hTERT Cells;背景說明：視網(wǎng)膜色素上皮；hTERT永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：alpha TC1.6細(xì)胞、NTERA2細(xì)胞、D-283MED細(xì)胞

L-cell Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC116細(xì)胞、TW-039細(xì)胞、NCI-H1755細(xì)胞

L-cell Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC116細(xì)胞、TW-039細(xì)胞、NCI-H1755細(xì)胞

HCM Cells;背景說明：心肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK-AD293細(xì)胞、AG 9細(xì)胞、WIL2-S細(xì)胞

PANC-03-27 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：hTERT-HME-1細(xì)胞、G 401細(xì)胞、HEK.EBNA細(xì)胞

UO31 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MHH-CALL-2細(xì)胞、MV-4:11細(xì)胞、293 HEK細(xì)胞

HCC-1438 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LN229細(xì)胞、PA I細(xì)胞、BpRcl細(xì)胞

LC1-Sq Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SCI1細(xì)胞、NBL-2細(xì)胞、Pa17C細(xì)胞

LC-MS Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH1963細(xì)胞、SNU601細(xì)胞、NCI-H2170細(xì)胞

143BTK- Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：混合型;相關(guān)產(chǎn)品有：H9細(xì)胞、NCIH1770細(xì)胞、HCEC細(xì)胞

HLCL9B10 Cells;背景說明：淋巴母細(xì)胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC1599細(xì)胞、8402細(xì)胞、BSC40細(xì)胞

GC-2 Cells;背景說明：精母細(xì)胞；SV４０轉(zhuǎn)化；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCAR 4細(xì)胞、C57/B6-L細(xì)胞、TSCC1細(xì)胞

TC-1/A9 Cells(提供STR鑒定圖譜)

RGC-6 Cells;背景說明：膠質(zhì)細(xì)胞株C６是由Benda等用N-nitrosomethylurea誘導(dǎo)的大鼠膠質(zhì)瘤克隆，并經(jīng)過一系列的體外培養(yǎng)和動(dòng)物傳代交替后建成的。 當(dāng)細(xì)胞從低密度生長到滿瓶時(shí)，S-１００產(chǎn)量增加１０倍。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RPMI7666細(xì)胞、RKO-AS45-1細(xì)胞、RCC10 RGB細(xì)胞

Liver-02 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC-4細(xì)胞、GM00637F細(xì)胞、Ca-Ski細(xì)胞

KP-N-RT Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成神經(jīng)細(xì)胞;相關(guān)產(chǎn)品有：NCIH1563細(xì)胞、Ca-Ski細(xì)胞、HG2855細(xì)胞

Hs819T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：成纖維;相關(guān)產(chǎn)品有：HS-766-T細(xì)胞、U2OS細(xì)胞、INS1-E細(xì)胞

RPMI 1788 Cells;背景說明：B淋巴細(xì)胞；EBV轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ca Ski細(xì)胞、BIU-87/Adr細(xì)胞、GM637A細(xì)胞

Hs600T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNK1細(xì)胞、Hs832T細(xì)胞、U20-S細(xì)胞

NTera 2/cl.D1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1155細(xì)胞、OVCAR432細(xì)胞、ssMCF-7細(xì)胞

H660 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：TE5細(xì)胞、MC3T3-E1(C4)細(xì)胞、UPCI-SCC-90細(xì)胞

VMM39 Cells;背景說明：黑色素瘤；神經(jīng)節(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A498細(xì)胞、SK-ML2細(xì)胞、KCL22細(xì)胞

CAL 39 Cells;背景說明：外陰鱗癌細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MM1S細(xì)胞、ETCC-007細(xì)胞、Karpas299細(xì)胞

Ly18 Cells;背景說明：彌漫大B細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH28細(xì)胞、NCIH1755細(xì)胞、DC 2.4細(xì)胞

SKG-IIIa Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２x１０^４ cells/ml;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：IOSE80細(xì)胞、SUM-190細(xì)胞、LS1034細(xì)胞

CHP-126 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAL-27細(xì)胞、PG-LH7細(xì)胞、G402細(xì)胞

LICR-HN-6 Cells;背景說明：舌鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE10細(xì)胞、H1836細(xì)胞、Tb1Lu細(xì)胞

DU 145人前列腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

BayGenomics ES cell line KST065 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB743 Cells(提供STR鑒定圖譜)

CMT93 Cells(提供STR鑒定圖譜)

MANEX7374O-9H8 Cells(提供STR鑒定圖譜)

S1F12 Cells(提供STR鑒定圖譜)

YSK Cells(提供STR鑒定圖譜)

" "PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=2744886; DOI=10.1002/ijc.2910440128

Hartley-Asp B., Billstrom A., Kruse E.

Identification by C-banding of two human prostate tumour cell lines, 1013L and DU 145.

Int. J. Cancer 44:161-164(1989)

PubMed=1873816

Isaacs W.B., Carter B.S., Ewing C.M.

Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Cancer Res. 51:4716-4720(1991)

PubMed=1574572; DOI=10.2307/3578273

Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.

Expression of the polymorphic human DNA repair gene XRCC1 does not correlate with radiosensitivity in the cells of human head and neck tumor cell lines.

Radiat. Res. 130:166-170(1992)

PubMed=8104329; DOI=10.1002/pros.2990230206

Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.

p53 oncogene mutations in three human prostate cancer cell lines.

Prostate 23:123-134(1993)

PubMed=8510267; DOI=10.1016/S0022-5347(17)35458-7

Effert P.J., McCoy R.H., Walther P.J., Liu E.T.-B.

p53 gene alterations in human prostate carcinoma.

J. Urol. 150:257-261(1993)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::aid-pros9>3.0.CO;2-H

Webber M.M., Bello D., Quader S.T.A.

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.

Prostate 30:58-64(1997)

PubMed=9214606; DOI=10.1093/carcin/18.6.1225

Webber M.M., Bello D., Kleinman H.K., Hoffman M.P.

Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells.

Carcinogenesis 18:1225-1231(1997)

PubMed=9460501; DOI=10.1016/S0165-4608(97)00060-5

Nupponen N.N., Hyytinen E.-R., Kallioniemi A.H., Visakorpi T.

Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.

Cancer Genet. Cytogenet. 101:53-57(1998)

PubMed=10702678; DOI=10.1159/000015432

Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.

Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::aid-mc6>3.0.CO;2-H

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::aid-gcc1076>3.0.CO;2-E

Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.

IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.

Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3

Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.

The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.

Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11280753

Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G., Gioffre C., Zhang H.-L., Chatterjee D., Pantazis P., Pommier Y.

Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.

Cancer Res. 61:1964-1969(2001)

PubMed=11304728; DOI=10.1002/pros.1045

van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.

Widely used prostate carcinoma cell lines share common origins.

Prostate 47:36-51(2001)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12606952; DOI=10.1038/sj.onc.1206247

Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.

Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.

Oncogene 22:1247-1252(2003)

PubMed=12615715

Reinhold W.C., Kouros-Mehr H., Kohn K.W., Maunakea A.K., Lababidi S., Roschke A.V., Stover K., Alexander J., Pantazis P., Miller L., Liu E.T.-B., Kirsch I.R., Urasaki Y., Pommier Y., Weinstein J.N.

Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.

Cancer Res. 63:1000-1011(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21

Russell P.J., Kingsley E.A.

Human prostate cancer cell lines.

Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290

van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.

Molecular characterization of human prostate carcinoma cell lines.

Prostate 57:205-225(2003)

CLPUB00698

van Bokhoven A.

Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.

Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15486987; DOI=10.1002/pros.20158

Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

Prostate 63:187-197(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=17440963; DOI=10.1002/pros.20581

Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T., Namiki M.

The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.

Prostate 67:955-967(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22275356; DOI=10.1074/jbc.M111.302547; PMCID=PMC3322861

Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K., Reginato M.J.

Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.

J. Biol. Chem. 287:11070-11081(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030

Lu Y.-H., Soong T.D., Elemento O.

A novel approach for characterizing microsatellite instability in cancer cells.

PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=23957452; DOI=10.3109/01913123.2013.814739

Gilloteaux J., Eze N., Jamison J.M., McGuire K., Summers J.L.

A rare, human prostate oncocyte cell originates from the prostatic carcinoma (DU145) cell line.

Ultrastruct. Pathol. 37:440-448(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

Data Brief 7:1302-1305(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30244336; DOI=10.1007/s00345-018-2501-6

Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.

Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.

World J. Urol. 37:1117-1126(2019)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574.1-3574.11(2019)"